Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.52 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7669379 | 1.00 | HTR3A (0.52) | HTR3AGABRA1GABRG2GABRB3JAK3 | |
| SCHEMBL28298503 | 0.92 | HTR3A (0.45) | HTR3AGABRA1GABRG2GABRB3JAK3 | |
| SCHEMBL27320198 | 0.91 | DRD2 (0.45) | HTR3ACYP2D6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9811537 | 0.88 | SLC18A3 (0.52) | HTR3AGABRA1GABRG2GABRB3SLC18A3 | |
| SCHEMBL18825946 | 0.77 | KDR (0.41) | GABRA1GABRG2GABRB3 | |
| SCHEMBL3089324 | 0.77 | — | — | |
| SCHEMBL31087550 | 0.75 | KDR (0.43) | SLC18A3 | |
| SCHEMBL146605 | 0.75 | KDR (0.43) | SLC18A3 | |
| SCHEMBL18722834 | 0.73 | HCAR2 (0.36) | GABRA1GABRG2GABRB3 | |
| SCHEMBL3014722 | 0.72 | PARP1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455548-B2 | FOR PROPHYLAXIS AND THERAPY OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS | MERCK & CO., INC. | 2002-09-24 | — | — | US | claimed |
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | BIAL - PORTELA & CA, S.A. (PT) | 2022-01-20 | — | — | US | disclosed |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | BIAL—PORTELA & CA, S.A. (PT) | 2021-04-13 | — | — | US | disclosed |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL-PORTELA & CA, S.A. (PT) | 2019-11-07 | — | — | US | disclosed |
| EP-3515433-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2019-07-31 | — | — | EP | disclosed |
| CN-109715155-A | blood brain barrier-penetrating agent dopamine- β -hydroxylase inhibitors | 巴尔-波特拉及康邦亚股份有限公司 | 2019-05-03 | — | — | CN | disclosed |
| WO-2018056854-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | BIAL - PORTELA & Cª, S.A. (PT) | 2018-03-29 | — | — | WO | disclosed |
| CN-1150165-C | 1-arylsulfonyl-2-aryl-pyrrolidine derivatives for the treatment of central nervous system disorders | - | 2004-05-19 | — | — | CN | disclosed |
| CN-1345311-A | 1-arenesulfonyl-2-aryl-pyrolidine and piperidine derivatives for treatment of CNS disorders | HOFFMANN LA ROCHE (CH) | 2002-04-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017523-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-ß-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | HTR3A 73/4885GABRA1 1120/4885GABRG2 2178/4885 |
| US-20190337950-A1 | BLOOD-BRAIN BARRIER-PENETRANT DOPAMINE-B-HYDROXYLASE INHIBITORS | DBH, SLC6A3, SLC6A2 | HTR3A 70/4885GABRA1 852/4885GABRG2 1656/4885 |
| US-10975083-B2 | Blood-brain barrier-penetrant dopamine-β-hydroxylase inhibitors | DBH, SLC6A3, SLC6A2 | HTR3A 66/4885GABRA1 1063/4885GABRG2 1992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.